|
[1]
|
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group[J]. Arch Ophthalmol, 1985, 103: 1796-1806. |
|
[2]
|
Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema[J]. Ophthalmology, 2008, 115:1447-1459. doi: 10.1016/j.ophtha.2008.06.015 |
|
[3]
|
Shah AM, Bressler NM, Jampol LM. Does laser still have a role in the management of retinal vascular and neovascular diseases?[J]. Am J Ophthalmol, 2011, 152:332-339. doi: 10.1016/j.ajo.2011.04.015 |
|
[4]
|
Cardillo JA, Melo LAS, Costa RA, et al. Comparison of intravitreal versus posterior sub-tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema[J]. Ophthalmology, 2005, 112:1557-1563. doi: 10.1016/j.ophtha.2005.03.023 |
|
[5]
|
Takata C, Messias A, Folgosa MS, et al. Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema[J]. Retina, 2010, 30:562-569. doi: 10.1097/IAE.0b013e3181c969b4 |
|
[6]
|
Bonini MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refr actory diabetic macular edema:a randomized clinical trial[J]. Invest Ophthalmol Vis Sci, 2005, 46:3845-3849. doi: 10.1167/iovs.05-0297 |
|
[7]
|
Choi YJ, Oh IK, Oh JR, et al. Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema[J]. Korean J Ophthalmol, 2006, 20:205-209. doi: 10.3341/kjo.2006.20.4.205 |
|
[8]
|
Yalcinbayir O, Gelisken O, Kaderli B, et al. Intravitreal versus sub-tenon posterior triamcinolone injection in bilateral diffu se diabetic macular edema[J]. Ophthalmologica, 2011, 225:222-227. doi: 10.1159/000324714 |
|
[9]
|
Qi HP, Bi S, Wei SQ, et al. Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema:a systematic review and Meta-analysis[J]. Curr Eye Res, 2012, 37:1136-1147. doi: 10.3109/02713683.2012.705412 |
|
[10]
|
Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy[J]. Arch Ophthalmol, 2006, 124:643-650. doi: 10.1001/archopht.124.5.643 |
|
[11]
|
Choi KS, Chung JK, Lim SH. Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema[J]. Korean J Ophthalmol, 2007, 21:11-17. doi: 10.3341/kjo.2007.21.1.11 |
|
[12]
|
Maia OO Jr, Takahashi BS, Costa RA, et al. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema:one-year results of a randomized clinical trial[J]. Am J Ophthalmol, 2009, 147:291-297. doi: 10.1016/j.ajo.2008.08.024 |
|
[13]
|
Mirshahi A, Shenazandi H, Lashay A, et al. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema[J]. Retina, 2010, 30:254-259. doi: 10.1097/IAE.0b013e3181b4f125 |
|
[14]
|
Liu L, Wu X, Geng J, et al. IVTA as adjunctive treatment to PRP and MPC for PDR and macular edema:a meta-analysis[J]. PLoS One, 2012, 7:e44683. doi: 10.1371/journal.pone.0044683 |
|
[15]
|
Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study):a 12-month, randomized, controlled, double-masked, multicenter phase Ⅱ study[J]. Diabetes Care, 2010, 33:2399-2405. doi: 10.2337/dc10-0493 |
|
[16]
|
Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study:ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118:615-625. doi: 10.1016/j.ophtha.2011.01.031 |
|
[17]
|
Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema:a placebo-controlled, randomized clinical trial[J]. Graefes Arch Clin Exp Ophthalmol, 2008, 246:483-489. doi: 10.1007/s00417-007-0688-0 |
|
[18]
|
Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12month data:report 2[J]. Ophthalmology, 2010, 117:10781086. https://pubmed.ncbi.nlm.nih.gov/20416952/ |
|
[19]
|
Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema[J]. Ophthalmology, 2009, 116:1142-1150. doi: 10.1016/j.ophtha.2009.01.011 |
|
[20]
|
Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema[J]. Retina, 2010, 30:1638-1645. doi: 10.1097/IAE.0b013e3181e1ed07 |
|
[21]
|
Zechmeister-Koss I, Huić M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema:a systematic review[J]. Br J Ophthalmol, 2012, 96:167-178. doi: 10.1136/bjophthalmol-2011-300674 |
|
[22]
|
Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)[J]. Br J Ophthalmol, 2008, 92:76-80. doi: 10.1136/bjo.2007.129122 |
|
[23]
|
Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2010, 117:1064-1077. doi: 10.1016/j.ophtha.2010.02.031 |
|
[24]
|
Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study[J]. Ophthalmology, 2009, 116:2175-2181. doi: 10.1016/j.ophtha.2009.04.023 |
|
[25]
|
Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2011, 118:609-614. doi: 10.1016/j.ophtha.2010.12.033 |
|
[26]
|
Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumabaugmented retinal laser photocoagulation in proliferative diabetic retinopathy:a randomized double-masked clinical trial[J]. Eur J Ophthalmol, 2008, 18:263-269. doi: 10.1177/112067210801800215 |
|
[27]
|
Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy[J]. Acta Ophthalmol, 2011, 89:e567-e572. doi: 10.1111/j.1755-3768.2011.02184.x |
|
[28]
|
Cho WB, Oh SB, Moon JW, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy[J]. Retina, 2009, 29:516-522. doi: 10.1097/IAE.0b013e31819a5fc2 |
|
[29]
|
Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)[J]. Retina, 2006, 26:1006-1013. doi: 10.1097/01.iae.0000246884.76018.63 |
|
[30]
|
Erdol H, Turk A, Akyol NN, et al. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy[J]. Retina, 2010, 30:570-577. doi: 10.1097/IAE.0b013e3181bf5ff0 |
|
[31]
|
Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for highrisk proliferative diabetic retinopathy (IBeHi study)[J]. Acta Ophthalmol, 2008, 86:385-389. doi: 10.1111/j.1600-0420.2007.01056.x |
|
[32]
|
Huang YH, Yeh PT, Chen MS, et al. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage[J]. Retina, 2009, 29:1134-1140. doi: 10.1097/IAE.0b013e3181b094b7 |
|
[33]
|
Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2008, 246:1699-1705. doi: 10.1007/s00417-008-0914-4 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
